Martindale Pharmaceuticals Limited Sustainability Profile
Martindale Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in Great Britain. Founded in 2000, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a strong operational presence across Europe and beyond, Martindale Pharmaceuticals focuses on key therapeutic areas, including pain management, anaesthesia, and critical care. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers. Notable achievements include regulatory approvals and partnerships that have enhanced its market position. Martindale Pharmaceuticals continues to be recognised for its dedication to improving patient outcomes through effective and accessible medication solutions.
DitchCarbon Score
How does Martindale Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Martindale Pharmaceuticals Limited's score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Martindale Pharmaceuticals Limited's reported carbon emissions
Martindale Pharmaceuticals Limited, headquartered in Great Britain, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Ethypharm SAS, any emissions data or climate commitments may be influenced by the parent company's initiatives. However, there are no documented reduction targets or climate pledges from Martindale Pharmaceuticals Limited at this time. The absence of emissions data suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. As part of the pharmaceutical industry, Martindale Pharmaceuticals Limited is likely to face increasing pressure to address carbon emissions and implement sustainable practices in line with global climate goals. For companies in this sector, it is essential to establish clear reduction targets and engage in initiatives that align with industry standards, such as those set by the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As Martindale Pharmaceuticals Limited progresses, it will be important to monitor their commitments and any future emissions data that may emerge.
How Carbon Intensive is Martindale Pharmaceuticals Limited's Industry?
How Carbon Intensive is Martindale Pharmaceuticals Limited's Location?
Martindale Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Martindale Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
